Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Icotinib (Conmana) is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity.
説明 | Icotinib (Conmana) is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. |
ターゲット&IC50 | EGFR:5 nM |
別名 | BPI-2009, BPI-2009H, Conmana |
分子量 | 391.42 |
分子式 | C22H21N3O4 |
CAS No. | 610798-31-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 72 mg/mL (183.9 mM)
Ethanol: 6 mg/mL(15.3 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Icotinib 610798-31-7 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Inhibitor BPI-2009 ErbB-1 BPI-2009H HER1 inhibit BPI 2009 BPI2009 Epidermal growth factor receptor Conmana inhibitor